InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has reported a significant growth in their second-quarter 2024 revenues, with a 177% increase to $8.6 million, and a substantial improvement in profitability, including a net profit of $0.95 million. This financial growth is attributed to the strong sales of its subsidiary BI Sky Global Ltd. and advancements in its innovative drug delivery technologies.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
